Aktuellt
SENASTE
Redeye notes another record quarter for BONESUPPORT and is encouraged by the persistent sales growth during a most peculiar year for elective surgeries. We reiterate our Base Case of SEK 80 and argue that the stock could soon see a fairer price closer to its peers, with a potential FDA approval as a clear trigger.
LÄS MER
